Patent SG-11201807596Y-A (SG)
Title: Gitr antibodies, methods, and uses
Inventor: HOLLAND CAM
IPC: A61K39/395
Filed: 2017-03-08
Abstract: Platefourth read .:COW03 4000900 2WC000 0 0 GT fl--Luc n Luc 4 \"•• cSL° \"cC1/4 W O 20 17 / 15 605 8 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/156058 Al 14 September 2017 (14.09.2017) WIPO I PCT 111111111111110111011111111111010111110 011111111111111111111111110111111111110111111 (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2017/021258 (22) International Filing Date: 8 March 2017 (08.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/305,270 8 March 2016 (08.03.2016) US 62/407,106 12 October 2016 (12.10.2016) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: HOLLAND, Cam; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). KEHOE, John; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). SNYDER, Linda; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). SEPULVEDA, Ale- jandro; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). VILLAREAL, Daniel; 2957 L Street, San Diego, California 92102 (US). (74) Agents: SHIRTZ, Joseph F. et al.; JOHNSON & JOHN- SON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) [Continued on next page] (54) Title: GITR ANTIBODIES, METHODS, AND USES Figure 1A (57) : Provided herein are antibodies that specifically bind to GITR. Also described are related polynucleotides capable of encoding the provided GITR-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or anti- gen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to enhance an immune response in a subject against cancer. WO 2017/156058 Al MIDEDIMOM0101011101010MOHOHNIREMEMOVOIS — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))